Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

TOKYO -- Roughly 2.5 million doses of oral COVID-19 medication bought by the Japanese government during the pandemic expired and were disposed of by the end of February, Nikkei has learned.

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID. The study ...

Paxlovid, available since December 2021, reduced the COVID-19 death rate in high-risk patients by 73%, a study found.

Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of ...